Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model

被引:55
作者
Telang, Sucheta [1 ]
Clem, Amy L. [1 ]
Eaton, John W. [1 ]
Chesney, Jason [1 ]
机构
[1] Univ Louisville, Mol Targets Grp, James Graham Brown Canc Ctr, Mol Targets Program, Louisville, KY 40202 USA
来源
NEOPLASIA | 2007年 / 9卷 / 01期
关键词
ascorbic acid; tumor; angiogenesis; collagen; prolyl hydroxylase;
D O I
10.1593/neo.06664
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis requires the deposition of type IV collagen by endothelial cells into the basement membrane of new blood vessels. Stabilization of type IV collagen triple helix depends on the hydroxylation of proline, which is catalyzed by the iron-containing enzyme prolyl hydroxylase. This enzyme, in turn, requires ascorbic acid to maintain the enzyme-bound iron in its reduced state. We hypothesized that dietary ascorbic acid might be required for tumor angiogenesis and, therefore, tumor growth. Here, we show that, not surprisingly, ascorbic acid is necessary for the synthesis of collagen type IV by human endothelial cells and for their effective migration and tube formation on a basement membrane matrix. Furthermore, ascorbic acid depletion in mice incapable of synthesizing ascorbic acid (Gulo(-/-)) dramatically restricts the in vivo growth of implanted Lewis lung carcinoma tumors. Histopathological analyses of these tumors reveal poorly formed blood vessels, extensive hemorrhagic foci, and decreased collagen and von Willebrand factor expression. Our data indicate that ascorbic acid plays an essential role in tumor angiogenesis and growth, and that restriction of ascorbic acid or pharmacological inhibition of prolyl hydroxylase may prove to be novel therapeutic approaches to the treatment of cancer.
引用
收藏
页码:47 / 56
页数:10
相关论文
共 49 条
[1]  
Bonanno E, 2000, IN VITRO CELL DEV-AN, V36, P336
[2]   ORTHOMOLECULAR TREATMENT OF CANCER .1. ROLE OF ASCORBIC-ACID IN HOST RESISTANCE [J].
CAMERON, E ;
PAULING, L .
CHEMICO-BIOLOGICAL INTERACTIONS, 1974, 9 (04) :273-283
[3]   SUPPLEMENTAL ASCORBATE IN SUPPORTIVE TREATMENT OF CANCER - PROLONGATION OF SURVIVAL TIMES IN TERMINAL HUMAN CANCER .1. [J].
CAMERON, E ;
PAULING, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1976, 73 (10) :3685-3689
[4]   SUPPLEMENTAL ASCORBATE IN SUPPORTIVE TREATMENT OF CANCER - RE-EVALUATION OF PROLONGATION OF SURVIVAL TIMES IN TERMINAL HUMAN CANCER [J].
CAMERON, E ;
PAULING, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1978, 75 (09) :4538-4542
[5]  
CAMERON E, 1979, CANCER RES, V39, P663
[6]   ORTHOMOLECULAR TREATMENT OF CANCER .2. CLINICAL TRIAL OF HIGH-DOSE ASCORBIC-ACID SUPPLEMENTS IN ADVANCED HUMAN CANCER [J].
CAMERON, E ;
CAMPBELL, A .
CHEMICO-BIOLOGICAL INTERACTIONS, 1974, 9 (04) :285-315
[7]   Ascorbic acid is a potent inhibitor of various forms of T cell apoptosis [J].
Campbell, JD ;
Cole, M ;
Bunditrutavorn, B ;
Vella, AT .
CELLULAR IMMUNOLOGY, 1999, 194 (01) :1-5
[8]   Vitamin C suppresses TNFα-induced NFκB activation by inhibiting IκBα phosphorylation [J].
Cárcamo, JM ;
Pedraza, A ;
Bórquez-Ojeda, O ;
Golde, DW .
BIOCHEMISTRY, 2002, 41 (43) :12995-13002
[9]  
Carr AC, 1999, AM J CLIN NUTR, V69, P1086
[10]  
CHATTERJEE I. B., 1970, Methods in Enzymology, V18A, P28, DOI 10.1016/0076-6879(71)18271-7